Xcout Intel
Valink Therapeutics competitors & alternatives
The 12 closest competitors and alternatives to Valink Therapeutics among biotechnology companies — ranked by similarity to what Valink Therapeutics actually does, not by market-cap band.
Subscribe to see Valink Therapeutics’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Valink Therapeutics
Valink Therapeutics Inc. is a biotechnology research company headquartered in Cambridge, Massachusetts, with a research and development subsidiary located in London, United Kingdom.
Valink Therapeutics at a glance
Valink Therapeutics is a biotechnology company headquartered in United States. Its most recent funding round, Seed, raised $11.8M in October 2025. Xcout tracks 11 named people at Valink Therapeutics, including Arne Scheu (Co-founder and Chief Executive Officer).
Valink Therapeutics leadership
- Arne ScheuCo-founder and Chief Executive Officer
- Irsyad KhairilFounder
- George ProcopiouVP, ADC Chemistry & Engineering
- Jolyon MartinDirector of BD & Strategy
- Steven O ConnellDirector of Operations
- Arne ScheuCEO & Director
5 more named people on record for Valink Therapeutics, with roles, board committees and tenure — see the full roster →
Valink Therapeutics funding rounds
Every round on record:
| Date | Round | Amount | Investors |
|---|---|---|---|
| Seed | $11.8M | 10 named |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Valink Therapeutics competitors
Ranked by semantic similarity — how close each company is to Valink Therapeutics by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Similar biotechnology company
Violet Therapeutics, Inc. is a therapeutics company headquartered in Cambridge, Massachusetts, utilizing novel proprietary platforms for drug development.
Similar biotechnology company
Apollo Therapeutics is a biopharmaceutical company with headquarters located in Cambridge, United Kingdom, alongside offices in Boston, Massachusetts. The company advances breakthrough science to build a portfolio of innovative therapeutics.
Similar biotechnology company
TRIMTECH Therapeutics is a biotechnology company headquartered in Cambridge, United Kingdom, focused on developing targeted protein degradation therapies like TRIMTAC and TRIMGLUE.
Similar biotechnology company
Pheon Therapeutics is a biotechnology research company headquartered in London, England, that specializes in developing next-generation antibody-drug conjugates for hard-to-treat cancers.
Similar biotechnology company
NextPoint Therapeutics is a private biopharmaceutical and technology company based in Cambridge, Massachusetts, focused on expanding novel therapeutic possibilities.
Similar biotechnology company
Delphia Therapeutics is a biotechnology research company headquartered in Cambridge, Massachusetts, with a team of 11 to 50 employees focused on therapeutic innovations.
Similar biotechnology company
Angiex Inc. is a private biotechnology company that focuses on novel biology to address the hallmarks of cancer lethality. The firm develops safe and effective cancer therapies and is located in Cambridge, Massachusetts.
Similar biotechnology company
Vibrant Therapeutics is a clinical-stage biotechnology company headquartered in Cambridge, Massachusetts, with operations in China. Founded in July 2019, the firm focuses on revolutionizing protein drug discovery and developing next-generation prodrugs with precise targeting.
Similar biotechnology company
Nuvalent, Inc. is a clinical-stage biopharmaceutical firm dedicated to pioneering novel therapeutic solutions for individuals battling cancer. The company's pipeline features two prominent drug candidates. One of these is NVL-520, a highly selective ROS1 inhibitor capable of penetrating the brain. This compound is specifically designed to target ROS1 fusions that possess the normal ROS1 kinase domain, and crucially, it retains activity against mutations known to confer resistance to both approved and experimental ROS1 inhibitors. NVL-520 is currently undergoing Phase I clinical evaluation. Nuvalent's second key asset is NVL-655, an ALK-selective inhibitor that also exhibits brain-penetrant properties. This therapy seeks to address significant limitations of earlier generations of ALK inhibitors (first-, second-, and third-generation), including the development of treatment resistance, central nervous system-related adverse effects, and brain metastases. NVL-655 is presently being assessed in Phase I/II clinical trials. The company was established in 2017 and is based in Cambridge, Massachusetts.
Similar biotechnology company
Mythic Therapeutics, Inc. is a biotechnology research company headquartered in Waltham, Massachusetts. The company is dedicated to developing a proprietary platform to enhance the effectiveness of antibody-drug conjugates and other antibody-based therapeutics.
Similar biotechnology company
Tasca Therapeutics is a biotechnology research company based in Cambridge, Massachusetts, leveraging a unique platform to exploit lipid-binding pockets on proteins.
Similar biotechnology company
Centauri Therapeutics Limited is a privately held immunotherapy company with its primary headquarters located in London, United Kingdom.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Valink Therapeutics and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Valink Therapeuticsand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →